Biocon Limited disclosed on August 06, 2026, that B S R & Co. LLP has resigned as the statutory auditor of its material subsidiary, Biocon Biologics Limited (BBL). The resignation takes immediate effect to align BBL’s statutory auditors with those of the holding company, driven by the mandatory rotation of B S R & Co. LLP as statutory auditors of Biocon Limited under the Companies Act, 2013.

The disclosure was made pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The information was submitted to the Bombay Stock Exchange and the National Stock Exchange of India Limited, referencing SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Auditor Transition Details

B S R & Co. LLP, identified by ICAI Firm Registration Number 101248W/W-100022, was originally appointed as statutory auditor of BBL via a shareholder resolution dated July 26, 2022. Their term was scheduled to expire at the conclusion of the annual general meeting held after the financial year ended March 31, 2027.

The firm confirmed it has completed all statutory obligations up to the date of resignation. This includes issuing the audit report for the year ended March 31, 2026, dated May 07, 2026, and the limited review report for the quarter ended June 30, 2026, dated August 05, 2026.

Regulatory Compliance and Next Steps

Partner Sanjay Sharma of B S R & Co. LLP stated that the firm would file Form ADT-3 with the Registrar of Companies in due course, as required by the Companies Act, 2013. The resignation letter and Annexure A, detailing the absence of any management-imposed limitations or other material concerns, were enclosed with the exchange filing.

What the Numbers Show

The resignation reflects a standard compliance-driven transition rather than an operational dispute. By aligning the subsidiary’s auditor with the parent company’s new statutory auditor, Biocon Limited ensures consolidated audit consistency. The timely completion of the FY26 audit and Q1FY27 limited review indicates no disruption to the financial reporting timeline for the period ending June 30, 2026.

Biocon Limited has published the audio and video recordings of its first quarter fiscal year 2027 (Q1 FY27) earnings call, providing investors with access to management commentary on the company’s recent financial performance. The earnings call was conducted on August 06, 2026, and the recordings are now available for review on the company’s official website. This disclosure ensures transparency and allows stakeholders to hear directly from executive leadership regarding operational updates and financial results for the period.

The release of these recordings is a mandatory compliance action under Indian securities law. Biocon Limited submitted the disclosure to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was issued from the company’s registered office in Electronic City, Bangalore.

Investors can access the audio and video files via the company’s investor relations portal. The specific link provided in the exchange filing directs users to the quarterly reports section for FY2026-27 on www.biocon.com . The same content is mirrored on the main corporate website to ensure broad accessibility for shareholders and analysts monitoring the biotechnology firm’s progress.

Disclosure Details

The following table outlines the key details of the regulatory filing:

The disclosure was authorized by Rajesh U. Shanoy, the Company Secretary and Compliance Officer of Biocon Limited. He holds ICSI Membership Number A16328 and digitally signed the communication on August 06, 2026, at 18:11:13 +05'30. The filing reference number is BIO/SECL/TG/2026-27/51.

What the Numbers Show

While this specific filing does not contain financial metrics such as net profit or revenue figures, the availability of the earnings call recording allows investors to analyze management’s tone and strategic focus for Q1 FY27. Analysts typically review these transcripts to gauge confidence in future growth trajectories, particularly in the biosimilars and biologics segments where Biocon operates. The prompt publication of the recording underscores the company’s adherence to corporate governance standards and its commitment to keeping equity stakeholders informed in real-time.